Status:
COMPLETED
A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Japanese Subjects With Palmoplantar Pustulosis
Lead Sponsor:
Amgen
Conditions:
Palmoplantaris Pustulosis
Eligibility:
All Genders
20+ years
Phase:
PHASE2
Brief Summary
This study will evaluate whether apremilast is better than placebo (inactive substance in the same form as the drug) for the treatment in Japanese subjects with PPP. This study also will evaluate the ...
Eligibility Criteria
Inclusion
- Subjects must satisfy the following criteria to be enrolled in the study:
- Subject has a diagnosis of Palmoplantar Pustulosis with or without pustulotic arthro-osteitis (PAO) for at least 24 weeks before screening.
- Subject has a total score of PPPASI: ≥ 12 at screening and baseline.
- Subject has moderate or severe pustules/vesicles on palms or soles (PPPASI severity score: ≥ 2) at screening and baseline.
- Subject has inadequate response to treatment with topical steroid and/or topical vitamin D3 derivative preparations prior to or at screening.
Exclusion
- The presence of any of the following will exclude a subject from enrollment:
- Subject has a diagnosis of plaque-type psoriasis.
- Subject has the presence of pustular psoriasis in any part of the body other than the palms and soles.
- Subject has obvious improvement during screening (≥ 5 PPPASI total score improvement during the screening).
- Subject has received any procedures for focal infection (e.g, tonsillectomy and dental therapy) within 24 weeks of baseline.
- Subject has periodontitis obviously requiring treatment at screening.
- Subject has chronic or recurrent tonsillitis or sinusitis requiring any continuous treatment for a month or more at screening.
- Subject has evidence of skin conditions of hands and feet that would interfere with evaluations of the effect of study medication.
- Subject is pregnant or breastfeeding.
Key Trial Info
Start Date :
October 16 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 7 2021
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT04057937
Start Date
October 16 2019
End Date
June 7 2021
Last Update
July 17 2024
Active Locations (22)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Ichinomiya, Aichi-ken, Japan, 491-8558
2
Research Site
Nagoya, Aichi-ken, Japan, 467-8602
3
Research Site
Fukuoka, Fukuoka, Japan, 814-0180
4
Research Site
Sapporo, Hokkaido, Japan, 060-0063